The ABL and JAK Tyrosine Kinase Pathways Are Co-Activated in BCR/ABL1 Positive Acute Lymphoblastic Leukemia

被引:0
|
作者
Bhagavathi, S. [1 ]
Aviv, H. [1 ]
机构
[1] Rutgers State Univ, New Brunswick, NJ USA
来源
JOURNAL OF MOLECULAR DIAGNOSTICS | 2016年 / 18卷 / 06期
关键词
D O I
暂无
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
H30
引用
收藏
页码:958 / 958
页数:1
相关论文
共 50 条
  • [41] Combined inhibition of BCR-ABL1 and the proteasome as a potential novel therapeutic approach in BCR-ABL positive acute lymphoblastic leukemia
    Maletzke, Saskia
    Salimi, Azam
    Vieri, Margherita
    Schroeder, Kema Marlen
    Schemionek, Mirle
    Masouleh, Behzad Kharabi
    Brummendorf, Tim H.
    Koschmieder, Steffen
    Appelmann, Iris
    PLOS ONE, 2022, 17 (10):
  • [42] Acute lymphoblastic leukemia associated with RCSD1–ABL1 novel fusion gene has a distinct gene expression profile from BCR–ABL1 fusion
    E De Braekeleer
    N Douet-Guilbert
    P Guardiola
    D Rowe
    S Mustjoki
    A Zamecnikova
    S Al Bahar
    G Jaramillo
    C Berthou
    N Bown
    K Porkka
    C Ochoa
    M De Braekeleer
    Leukemia, 2013, 27 : 1422 - 1424
  • [43] BCR::ABL1-Positive Acute Myeloid Leukemia
    Canali, Alban
    Rieu, Jean-Baptiste
    Lapierre, Leopoldine
    Bain, Barbara J.
    AMERICAN JOURNAL OF HEMATOLOGY, 2025,
  • [44] Jumping translocation of 1q in BCR/ABL-positive acute lymphoblastic leukemia
    Bilic, Masha
    Quigley, Denise I.
    Stuart, Robert K.
    Wolff, Daynna J.
    CANCER GENETICS AND CYTOGENETICS, 2007, 172 (01) : 90 - 91
  • [45] Jumping translocation of 1q in a BCR/ABL-positive acute lymphoblastic leukemia
    Pelz, AF
    Müller, G
    Wieacker, P
    CANCER GENETICS AND CYTOGENETICS, 2005, 157 (02) : 157 - 159
  • [46] BCR::ABL1 tyrosine kinase inhibitors hamper the therapeutic efficacy of blinatumomab in vitro
    Joseph Kauer
    Melanie Märklin
    Martin Pflügler
    Sebastian Hörner
    Clemens Hinterleitner
    Claudia Tandler
    Gundram Jung
    Helmut R. Salih
    Jonas S. Heitmann
    Journal of Cancer Research and Clinical Oncology, 2022, 148 : 2759 - 2771
  • [47] BCR::ABL1 tyrosine kinase inhibitors hamper the therapeutic efficacy of blinatumomab in vitro
    Kauer, Joseph
    Maerklin, Melanie
    Pfluegler, Martin
    Hoerner, Sebastian
    Hinterleitner, Clemens
    Tandler, Claudia
    Jung, Gundram
    Salih, Helmut R.
    Heitmann, Jonas S.
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2022, 148 (10) : 2759 - 2771
  • [48] Involvement of BCR::ABL1 in laminin adhesion of Philadelphia chromosome-positive acute lymphoblastic leukemia through upregulation of integrin α6
    Takahashi, Kazuya
    Nguyen, Thao Thu Thi
    Watanabe, Atsushi
    Sato, Hiroki
    Saito, Kinuko
    Tamai, Minori
    Harama, Daisuke
    Kasai, Shin
    Akahane, Koshi
    Goi, Kumiko
    Kagami, Keiko
    Abe, Masako
    Komatsu, Chiaki
    Maeda, Yasuhiro
    Sugita, Kanji
    Inukai, Takeshi
    CANCER REPORTS, 2024, 7 (04)
  • [49] Amplification of the BCR::ABL1 Fusion Gene: A Rare Phenomenon in B-cell Acute Lymphoblastic Leukemia
    Ray, Debadrita
    Sharma, Praveen
    Jain, Arihant
    Sreedharanunni, Sreejesh
    TURKISH JOURNAL OF HEMATOLOGY, 2023, 40 (03) : 204 - 205
  • [50] PARP1 Characterization as a Potential Biomarker for BCR::ABL1 p190+Acute Lymphoblastic Leukemia
    Machado, Caio Bezerra
    da Silva, Emerson Lucena
    Ferreira, Wallax Augusto Silva
    Pessoa, Flavia Melo Cunha de Pinho
    de Quadros, Andreza Urba
    Fantacini, Daianne Maciely Carvalho
    Furtado, Izadora Peter
    Rossetti, Rafaela
    Silveira, Roberta Maraninchi
    de Lima, Sarah Caroline Gomes
    Mello Junior, Fernando Augusto Rodrigues
    Seabra, Aline Damasceno
    Moreira, Edith Cibelle de Oliveira
    de Moraes Filho, Manoel Odorico
    de Moraes, Maria Elisabete Amaral
    Montenegro, Raquel Carvalho
    Ribeiro, Rodrigo Monteiro
    Khayat, Andre Salim
    Burbano, Rommel Mario Rodriguez
    de Oliveira, Edivaldo Herculano Correa
    Covas, Dimas Tadeu
    de Souza, Lucas Eduardo Botelho
    Moreira-Nunes, Caroline de Fatima Aquino
    CANCERS, 2023, 15 (23)